FDA OKs new diabetes pill from Lilly, Boehringer
The Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients who can't control their blood sugar with older medicines.
Health Care Businesses
Articles
Developer plans $13M senior-living center in Westfield
Cicero-based developer Mainstreet Property Group LLC plans to build a $13.3 million senior health care center in Westfield. The 65,000-square assisted living facility will employ about 150 people when it opens in 2012.
Lilly teams with Medtronic on Parkinson’s treatment
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
Much unknown about new Cook Group CEO
Carl Cook has been tabbed to replace his father, Bill Cook, who died a week ago. But many in the Bloomington business community know little about him, which reflects the company’s strict privacy policy.
Lilly shareholders fail to remove anti-takeover measures
A proposal that would have weakened Eli Lilly and Co.’s defenses against an unwanted takeover failed to pass Monday despite a large majority of shareholders voting to remove those barriers for the second straight year.
Lilly shares falter after quarterly earnings report
Eli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped anyway Monday morning, along with the broader market.
FDA wants further testing of Lilly pancreas drug
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
Indiana panel OKs criminal checks on medical workers
Physicians, dentists, nurses, veterinarians, pharmacists and other medical workers would have to undergo a criminal background check when applying for a new state license under a bill approved Tuesday by an Indiana House committee.
Arcadia in danger of stock exchange delisting
The Indianapolis-based health care company’s stock, which trades on the NYSE Amex Equities exchange, has closed at an average price of less than 20 cents over a consecutive 30-day trading period, triggering the warning.
Antidepressants linked to narrowed arteries
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based drugmaker.
Drugmaker Lilly launches global service program
Eli Lilly and Co. is starting a service program that sends employees around the world to help developing communities and learn about other cultures, as the drugmaker looks to international markets.
Regulators delay approval of Lilly’s Alzheimer’s screen
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
Trade agency to probe Lilly’s infringement claim
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Lilly’s Bydureon falls short of competitor in study
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
UPDATE: Bioanalytical researcher opening lab in Indianapolis
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.
UPDATE: Lilly settles pollution suit for $337,500
A complaint filed Wednesday by the U.S. government says Lilly’s plant on South Harding Street is emitting high levels of acetonitrile and methanol, considered hazardous air pollutants by the EPA.
Eli Lilly neuroscience chief resigns
David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.
Lilly takeover provision to be voted on again
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board is on the agenda of the company’s April 18 annual meeting.
Repeated price cuts take glow off Endocyte IPO
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
Health insurers expect hit from reform rule
Major health insurers, including WellPoint, say a provision that requires them to spend a certain percentage of the premiums they collect on care-related costs will eat into earnings this year.